anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Ranolazine
Trial phase: Not Applicable
ATC code: C01EB18
SMILES: COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Ranolazine 500 mg BID
Eligibility criteria:
Inclusion Criteria:

- Patients with subjective symptoms of ischemia without flow limiting angiographic CAD (<50% epicardial coronary stenosis) and abnormal IMR (>20 U).

Definition of ischemia (any one):

chest pain with dynamic ischemic ECG changes (t wave inversions or > 1 mm ST depressions
Exercise treadmill testing induced chest pain with ≥1 mm of downsloping or flat ST segment depression during exercise or recovery; ≥2 mm of ischemic ST depression at a low workload (stage 2 or less or ≤130 beats/min); early onset (stage 1) or prolonged duration (>5 min) of ST depression; multiple leads (>5) with ST depression
Nuclear stress perfusion defect > 10%
Stress echocardiogram with stress induced wall motion abnormality

Exclusion Criteria:

- Age < 18 yrs
Flow Limiting epicardial CAD >50%
Life expectancy < 6 months
Recent (<1 week) myocardial infarction or positive biomarkers
Severe aortic stenosis
Contraindications to IMR testing including inability to utilize antithrombotic therapy and/or intravenous adenosine
Contraindications to Ranolazine therapy:
Patients with known hepatic insufficiency, prolonged QT or renal failure (GFR < 60)
use of drugs that inhibit CYP3A such as diltiazem, verapamil, ketoconazole, macrolides and HIV protease inhibitors
Pregnancy, breastfeeding
Patients taking drugs which prolong QT interval
Intervention: Nikethamide
Trial phase: Phase 1 | Phase 2
ATC code: R07AB02 | R07AB52
SMILES: CCN(CC)C(=O)c1cccnc1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 36
Group description: NiCord® is a stem/progenitor cell based product composed of ex vivo expanded allogeneic UCB cells.

NiCord®
Eligibility criteria:
Inclusion Criteria:

Applicable disease and eligible for myeloablative SCT
Patients must have two partially HLA-matched CBUs
Back-up stem cell source
Adequate Karnofsky Performance score or Lansky Play-Performance scale
Sufficient physiological reserves
Signed written informed consent

Exclusion Criteria:

HLA-matched donor able to donate
Prior allogeneic HSCT
Other active malignancy
Active or uncontrolled infection
Active/symptoms of central nervous system (CNS) disease
Pregnancy or lactation
Intervention: FLUTICASONE PROPIONATE
Trial phase: Phase 3
ATC code: D07AC17 | R01AD08 | R01AD58 | R03BA05
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 314
Group description: Two sprays of Fluticasone propionate nasal spray (50 mcg/spray) per nostril to be administered in morning (Total dose 200 mcg).
Eligibility criteria:
Inclusion Criteria:

Participants with good general health (in the opinion of the investigator) with no clinically significant and relevant abnormalities of medical history

Participants with diagnosis of seasonal allergic rhinitis

A clinical history (written or verbal confirmation) of allergic rhinitis with the seasonal onset and offset of nasal and ocular allergy symptoms during each of the last 2 mountain cedar pollen allergy seasons.
A positive skin test reaction to (at least) the relevant allergen, mountain cedar pollen, as determined by the skin pricks method performed within 12 months of Visit 1).

Participants with allergic rhinitis symptom of at least moderate severity for randomization:

An iTOSS of ≥ 4 and an iNCSS of ≥2 on the morning of randomization (Visit 3/Baseline).
An averaged (rTOSS) of ≥ 4, and an averaged rNCSS of ≥2 for three of the five days during the placebo lead in
Participant residing within a geographical environment where exposure to mountain cedar pollen is significant during the entire study period.
Participant demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent/assent and has received a signed and dated copy of the informed consent/assent form. Children, ages 12 to 17 will be required to sign an assent form as part of the informed consent process.

Exclusion Criteria:

Participants with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.

Participants with nasal disorders like:

injury or surgery to their nose that the investigator believes would interfere with participation in the study.
previously diagnosed with a severe physical obstruction of the nose (e.g., deviated septum) that could affect the deposition of double-blind intranasal study drug.
Rhinitis medicamentosa
Participants who have historical or current evidence of clinically significant uncontrolled disease like asthma, cardiac arrhythmias, hypertension, diabetes mellitus, ocular herpes, glaucoma, hepatic or renal disease, malignancy etc.
Presence of or symptoms of an active bacterial or viral infection.
Participants who have conjunctivitis caused by an infectious agent.
Participants with current, single eye or bilateral cataracts or participants who had cataract surgery within/less than 3 months
Intervention: Trazodone
Trial phase: Not Applicable
ATC code: N06AX05
SMILES: O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Subjects will receive trazodone during their treatment night sleep study

Trazodone: Subjects will receive trazodone during one of their treatment arm studies
Eligibility criteria:
Inclusion Criteria for OSA Patients:

OSA (elevated AHI).
Age range 18-70 years.

Exclusion Criteria:

Any known cardiac (apart from treated hypertension), pulmonary (including asthma), renal, neurologic (including epilepsy), neuromuscular, or hepatic disease.
Susceptible to stomach ulcers.
Pregnant women.
History of hypersensitivity to Afrin, Lidocaine, trazodone and/or donepezil.
History of bleeding diathesis and/or gastrointestinal bleeding.
Use of any medications that may affect sleep or breathing.
A psychiatric disorder, other than mild depression; e.g. schizophrenia, bipolar disorder, major depression, panic or anxiety disorders.
Substantial cigarette (>5/day), alcohol (>3oz/day) or use of illicit drugs.
More than 10 cups of beverages with caffeine (coffee, tea, soda/pop) per day.
Desaturations to below 70% lasting greater than 10 seconds in duration per event on polysomnography.
Intervention: Fidaxomicin
Trial phase: Phase 4
ATC code: A07AA12
SMILES: CCc1c(Cl)c(O)c(Cl)c(O)c1C(=O)OC1C(C)OC(OCC2=CC=CCC(O)C(C)=CC(CC)C(OC3OC(C)(C)C(OC(=O)C(C)C)C(O)C3O)C(C)=CC(C)=CCC(C(C)O)OC2=O)C(OC)C1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 34
Group description: Fidaxomicin 200mg by mouth every 12 hours for 10 days

Fidaxomicin: Fidaxomicin 200mg by mouth every 12 hours for 10 days
Eligibility criteria:
Inclusion Criteria:

18 years of age and above
First diagnosis of C. difficile infection
Treatment for C. difficile infection less than 24 hours
Female subjects must be nonpregnant, nonlactating, and either postmenopausal for at least 1 year, surgically sterile (i.e., documented tubal ligation or hysterectomy) for at least 90 days, abstinent, or agree to use 1 of the following forms of contraception from the time of signing the Informed Consent form (ICF) until 30 days after leaving the study site: a nonhormonal intrauterine device (IUD) with spermicide, female condom with spermicide, contraceptive sponge with spermicide, diaphragm with spermicide, cervical cap with spermicide, a male sexual partner who agrees to use a male condom with spermicide, or a sterile sexual partner.

Exclusion Criteria:

History of hypersensitivity to fidaxomicin or vancomycin
Pregnant or breast-feeding
Active treatment with other therapies with activity against C. difficile
Receiving any peristaltic agents
Medical history including ulcerative colitis or Chron's disease
Ordered to be nothing by mouth or cannot swallow the study medication
Participation in another clinical research study utilizing pharmacological treatment within 1 month or five half-lives of the medication whichever is longer
Any other reason felt by the investigator to potentially affect the outcomes of the study
Intervention: Vancomycin
Trial phase: Phase 4
ATC code: A07AA09 | J01XA01 | S01AA28
SMILES: CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 34
Group description: Vancomycin 125mg by mouth every 6 hours for 10 days

Vancomycin: Vancomycin 125mg by mouth every 6 hours for 10 days
Eligibility criteria:
Inclusion Criteria:

18 years of age and above
First diagnosis of C. difficile infection
Treatment for C. difficile infection less than 24 hours
Female subjects must be nonpregnant, nonlactating, and either postmenopausal for at least 1 year, surgically sterile (i.e., documented tubal ligation or hysterectomy) for at least 90 days, abstinent, or agree to use 1 of the following forms of contraception from the time of signing the Informed Consent form (ICF) until 30 days after leaving the study site: a nonhormonal intrauterine device (IUD) with spermicide, female condom with spermicide, contraceptive sponge with spermicide, diaphragm with spermicide, cervical cap with spermicide, a male sexual partner who agrees to use a male condom with spermicide, or a sterile sexual partner.

Exclusion Criteria:

History of hypersensitivity to fidaxomicin or vancomycin
Pregnant or breast-feeding
Active treatment with other therapies with activity against C. difficile
Receiving any peristaltic agents
Medical history including ulcerative colitis or Chron's disease
Ordered to be nothing by mouth or cannot swallow the study medication
Participation in another clinical research study utilizing pharmacological treatment within 1 month or five half-lives of the medication whichever is longer
Any other reason felt by the investigator to potentially affect the outcomes of the study
Intervention: Zidovudine
Trial phase: Phase 4
ATC code: J05AF01 | J05AR01 | J05AR04 | J05AR05
SMILES: Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 25
Group description: Severe Acute Malnutrition at Entry ZDV+3TC+LPV/r
Eligibility criteria:
Inclusion Criteria:

Documentation of HIV-1 infection defined as positive results from two samples collected at different time points, using protocol-specified tests
Meets WHO classification for severe malnutrition, normal nutrition status, or mild malnutrition
Eligible for HAART defined by WHO 2013 pediatric guidelines
Parent or legal guardian able and willing to provide signed informed consent, remain within the study area during the study period and agree to have subject followed at the clinical site
Qualifying hematology and chemistry laboratory values obtained from specimens collected within the study-specific screening period
For severely malnourished children: An inpatient in a nutrition rehabilitation unit. Clinical improvement after 10-18 days on nutrition rehabilitation defined as: Appetite returned and eating better - child shows interest in food even if does not complete amount given:
No further weight loss
Normalized sodium and potassium defined as severity grade 1 or lower
No evidence of cardiac failure
Loss of apathy and starting to play
No hypothermia or pyrexia - temperature stable at >35.0 to <38.0° C (non-axillary) or >34.4 to <37.4° C (axillary)

For children with normal - mild malnutrition, clinical stability will be indicated by:

Good appetite
Normalized sodium and potassium defined as severity grade 1 or lower
No hypothermia or pyrexia - temperature stable at >35.0 to <38.0° C (non-axillary) or >34.4 to <37.4° C (axillary)

Exclusion Criteria:

Edematous malnutrition at the time of study entry
≥ Grade 3 respiratory distress or presence of cardio respiratory compromise within 3 days prior to entry
Chemotherapy for malignancy
Acute infection for which the child has received appropriate antimicrobial treatment for <5 days
Tuberculosis disease
Clinic hepatitis as evidenced by jaundice and hepatomegaly
Taking any disallowed medications
Any condition, situation, or clinical finding that in the opinion of the investigator would place the child at an unacceptable level of risk for injury, or render the child/caregiver(s) unable to meet the requirements of the study, interfere with study participation, or in the interpretation of study results.
Intervention: Zidovudine
Trial phase: Phase 4
ATC code: J05AF01 | J05AR01 | J05AR04 | J05AR05
SMILES: Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 27
Group description: Normal Nutrition or Mild Malnutrition at Entry ZDV+3TC+LPV/r
Eligibility criteria:
Inclusion Criteria:

Documentation of HIV-1 infection defined as positive results from two samples collected at different time points, using protocol-specified tests
Meets WHO classification for severe malnutrition, normal nutrition status, or mild malnutrition
Eligible for HAART defined by WHO 2013 pediatric guidelines
Parent or legal guardian able and willing to provide signed informed consent, remain within the study area during the study period and agree to have subject followed at the clinical site
Qualifying hematology and chemistry laboratory values obtained from specimens collected within the study-specific screening period
For severely malnourished children: An inpatient in a nutrition rehabilitation unit. Clinical improvement after 10-18 days on nutrition rehabilitation defined as: Appetite returned and eating better - child shows interest in food even if does not complete amount given:
No further weight loss
Normalized sodium and potassium defined as severity grade 1 or lower
No evidence of cardiac failure
Loss of apathy and starting to play
No hypothermia or pyrexia - temperature stable at >35.0 to <38.0° C (non-axillary) or >34.4 to <37.4° C (axillary)

For children with normal - mild malnutrition, clinical stability will be indicated by:

Good appetite
Normalized sodium and potassium defined as severity grade 1 or lower
No hypothermia or pyrexia - temperature stable at >35.0 to <38.0° C (non-axillary) or >34.4 to <37.4° C (axillary)

Exclusion Criteria:

Edematous malnutrition at the time of study entry
≥ Grade 3 respiratory distress or presence of cardio respiratory compromise within 3 days prior to entry
Chemotherapy for malignancy
Acute infection for which the child has received appropriate antimicrobial treatment for <5 days
Tuberculosis disease
Clinic hepatitis as evidenced by jaundice and hepatomegaly
Taking any disallowed medications
Any condition, situation, or clinical finding that in the opinion of the investigator would place the child at an unacceptable level of risk for injury, or render the child/caregiver(s) unable to meet the requirements of the study, interfere with study participation, or in the interpretation of study results.
Intervention: FOLIC ACID
Trial phase: Not Applicable
ATC code: B03AD01 | B03AD02 | B03AD03 | B03AD04 | B03AD05 | B03AE01 | B03AE02 | B03BB01 | B03BB51 | V04CX02
SMILES: Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 15
Group description: Folic acid 4 mg buccally 3 hours prior to D&E as an adjunct to same-day Dilapan-S
Eligibility criteria:
Inclusion Criteria:

Age greater than or equal to 18 years (no upper age limit)
Gestational age between 16+0 and 20+6 weeks gestation on day of D&E with confirmation of gestational age by ultrasound
Desires D&E for termination of pregnancy or for fetal demise
Able to provide written informed consent
Able to comply with study procedures
English-speaking

Exclusion Criteria:

Known allergy or contraindication to misoprostol
Pregnancy with a multiple gestation
Known bleeding disorder or current anticoagulation therapy (within one month of procedure)
Active bleeding or hemodynamically unstable at enrollment
Signs of chorioamnionitis or clinical infection at enrollment
Signs of spontaneous labor or cervical insufficiency at enrollment
Intervention: Atropine
Trial phase: Phase 4
ATC code: A03BA01 | A03BA03 | A03CB03 | A03CB31 | S01FA01
SMILES: CN1C2CCC1CC(OC(=O)C(CO)c1ccccc1)C2
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 60
Group description: This group consists of children who are ASA physical status I and II, less than 2 years of age and scheduled for elective surgical procedure and weigh less than 5Kg will receive atropine 5 mcg/kg IV during sevoflurane anesthesia.

Atropine: IV dose at 5 mcg/kg
Eligibility criteria:
Inclusion Criteria:

Age : 0-2 years old
Weight : less than the 95th percentile for age and height ( no more than 15kg )
ASA classification : I-II
Meets the hospital and department of anesthesiology guidelines with respect to peri-operative care

Exclusion Criteria:

History of heart disease
Any condition predisposing to arrhythmia
Any medication known to influence the heart rate
Child taking anti-cholinergic medication routinely
The use of succinylcholine anticipated (will cause bradycardia)
Rapid sequence intubation is required (due to aspiration risk)
Known difficult airway (may be difficult to bag mask ventilate)
Intervention: Baclofen
Trial phase: Phase 2
ATC code: M03BX01
SMILES: NCC(CC(=O)O)c1ccc(Cl)cc1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 22
Group description: Baclofen will be dispensed in pill form. Baclofen will be prescribed at 20 mg 4 times per day. Each baclofen pill will be 10 mg. Thus, 2 pills will be taken at each scheduled dose for a total of 8 pills a day over a period of 8 weeks. In this way, the titration schedule, taper and potential dose reductions can be managed.

Baclofen
Eligibility criteria:
Inclusion Criteria:

Physically healthy, as determined by a comprehensive physical examination and approval of the study physician males or females who smoke cigarettes, ages 18-60.
Smoke ≥ 6 cigarettes per day for at least 6 months prior to study start date.
Females must be non-pregnant, non-lactating and either be of non-childbearing potential (i.e. sterilized via hysterectomy or bilateral tubal ligation or at least 1 year post-menopausal) or of child bearing potential but practicing a medically acceptable method of birth control. Examples of medically acceptable methods for this protocol include barrier (diaphragm or condom) with spermicide, an intrauterine device (IUD), the Nuvaring, oral contraceptives, levonorgestrel implant, hormonal injection or complete abstinence.
Provide voluntary informed consent.
Must be able to read. [Subjects are required to be able to read because there are several self-administered measures that they must read, understand and provide written answers.]
Intelligence quotient of ≥ 80.

Exclusion Criteria:

History of head trauma or injury causing loss of consciousness, lasting more than five (5) minutes or associated with skull fracture or inter-cranial bleeding or abnormal MRI.
Current Diagnostic and Statistical Manual-IV (DSM-IV) Axis I diagnoses other than nicotine dependence.
Presence of magnetically active irremovable prosthetics, plates, pins, permanent retainer, bullets, etc. (unless a radiologist confirms that it's presence is unproblematic). An x-ray may be obtained to determine eligibility given the possibility of a foreign body.
History of psychosis.
Claustrophobia or other medical condition preventing subject from lying in the MRI for approximately one (1) hour.
Current diagnosis of or treatment within the last 3 months for alcohol dependence.
Current use of any smoking cessation treatments such as Zyban, Chantix, Wellbutrin, patch, gum, inhaler, electronic cigarettes, herbal preparations.
Vision problems that cannot be corrected with glasses.
Weight exceeding 300 pounds [Imaging data acquisition is impaired with high weight individuals].
History of stroke.
Intervention: Diethylstilbestrol
Trial phase: Phase 2
ATC code: G03CB02 | G03CC05 | L02AA01 | L02AA04
SMILES: CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 3
Group description: Oral Budesonide

Oral Budesonide: This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day. Children < 10 years will receive 1 mg daily. Children 10 years and older will receive 2 mg daily.
Eligibility criteria:
Inclusion Criteria

Signed written informed consent and assent if applicable prior to performing any study specific procedure.
Male or female subjects aged 3-17 years old.
Diagnosis of EoE within 2 months of enrollment (greater than or equal to 15 eosinophils per high powered field in both proximal or distal esophageal specimens).
Subjects who have failed at least a two month trial of proton pump inhibitor.
A female subject of childbearing potential who is or may become sexually active agrees to routinely use contraception from the time of signing informed consent and assent until 30 days from end of study.
Positive allergy testing on prick and/or patch testing.

Exclusion Criteria

Subjects who are responsive to at least a two month trial of a proton pump inhibitor.
Diagnosis of Inflammatory Bowel Disease or static encephalopathy.
Prior abdominal surgery and other organ disorder not including atopic diseases.
Previous esophageal surgical procedure.
Previous esophageal congenital disorders such as tracheal esophageal fistula and esophageal atresia.
Positive for pregnancy.
Previous therapy within 6 weeks with oral or swallowed steroids or strict dietary elimination of major allergens
Presence of increased eosinophils in the stomach, small intestine, large intestine, and colon based on Debrosse et al.
Intervention: Naltrexone
Trial phase: Not Applicable
ATC code: A08AA62 | N02AA56 | N07BB04
SMILES: [H][C@@]12Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@]([H])(C4)[C@]3(O)CCC2=O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 76
Group description: One dose of intramuscular injection of 380mg extended-release naltrexone.

Extended release naltrexone
Eligibility criteria:
Summary Inclusion Criteria:

Diagnostic and Statistical Manual (DSM)-IV Methamphetamine Dependence
Deemed healthy enough to participate by study physician
Age 18-55
Right handed
English-speaking

Summary Exclusion Criteria:

Current opioid use in the last 30 days; opioid abuse or dependence within past 5 years
Pregnancy
MRI contraindications (e.g. metal in head).

The research is conducted in Portland, OR.
Intervention: OXYTOCIN
Trial phase: Not Applicable
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 106
Group description: single dose of 24 IU oxytocin, self-administered intranasally (IN)

Oxytocin spray: single dose of 24 IU oxytocin, self-administered intranasally (IN)
Eligibility criteria:
Inclusion Criteria:

Between the ages of 18-30 years or 63-85 years
English fluency
Caucasian
Right-handed

Exclusion Criteria:

Pregnant or possibly pregnant
Breastfeeding
Claustrophobia
Currently on vasoconstrictors, pseudoephedrine or antidiuretic medication
Large pieces of metal in the body, particularly in the face or neck
Piercings or metal implants that cannot be removed from the body
Surgery on the brain or any prior serious brain damage or disease
Dementia or severe cognitive disorders
History of hyponatremia, Syndrome of Inappropriate Antidiuretic Hormone, psychogenic polydipsia, or motion disorder